Hypoxia inducible VEGF plasmid for ischemic disease

Details Hypoxia inducible VEGF plasmid for ischemic disease Hypoxia inducible VEGF plasmid for ischemic disease

2011-08-16

2011-08-16

Whiteman, Brian (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

Reexamination Certificate

active

07998941

ABSTRACT:
Plasmids useful for treating ischemic disease, such as ischemic heart disease, are described. The plasmids express vascular endothelial growth factor (VEGF) under the control of a promoter (RTP801) that is up-regulated under hypoxic conditions. Pharmaceutical compositions for treating ischemic disease include mixtures of the hypoxia-regulated VEGF plasmids and pharmaceutically acceptable carriers. Methods for treating ischemic disease include administering such pharmaceutical compositions to a person in need of such treatment.

REFERENCES:
patent: 6548633 (2003-04-01), Edwards et al.
patent: 2003/0104973 (2003-06-01), Einat et al.
Ellisen et al. Molecular Cell 2002, 10: 995-1005.
Tzipora Shoshani, et al., Identification of a Novel Hypoxia-Inducible Factor 1-Responsive Gene, RtP801, Involved in Apoptosis, Molecular and Cellular Biology, Apr. 2002, p. 2283-2293.
Hua Su, et al., Adeno-Associated Viral Vector-Mediated Hypoxia Response Element-Regulated Gene Expression in Mouse Ischemic Heart Model, Proceedings of the National Academy of Sciences of USA (PNAS), Jul. 2002, p. 9480-9485, vol. 99, No. 14.
Yukio Tsurumi, et al., Direct Intramuscular Gene Transfer of Naked DNA Encoding Vascular Endothelial Growth Factor Augments Collateral Development and Tissue Perfusion, American Heart Association Circulation, Dec. 1996, p. 3281-3290, vol. 94, No. 12.
M Lee, et al., Hypoxia-Inducible VEGF Gene Delivery to Ischemic Myocardium Using Water-Soluble Lipopolymer, Gene Therapy, 2003, p. 1535-1542.
Minhyung Lee, et al., Sp1-Dependent Regulation of the RTP801 Promoter and Its Application to Hypoxia-Inducible VEGF Plasmid for Ischemic Disease, Pharmaceutical Research, p. 736-741, May 2004, vol. 21, No. 5.
Seppo Yia-Herttuala, et al., Cardiovascular Gene Therapy, The Lancet, Jan. 2000, p. 213-222, vol. 355.
PGL3 Luciferase Reporter Vectors, Promega Catalog, 2008.
Lin Lin, et al., Arsenite Induces a Cell Stress-Response Gene, RTP801, Through Reactive Oxygen Species and Transcription Factoprs ELK-1 and CCAAT/Enhancer-Binding Protein, Biochem J., 2005, p. 93-102.
Jeffrey M. Isner, Myocardial Gene Therapy, Nature, Jan. 2002, p. 234-239, vol. 415.
Mark W. Majesky, A Little VEGF Goes a Long Way: Therapeutic Angiogenesis by Direct Injection of Vascular Endothelial Growth Factor-Encoding Plasmid DNA, American Heart Association Circulation, 1996, p. 3062-3064.

Affiliated with

Also associated with

Rating

Hypoxia inducible VEGF plasmid for ischemic disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hypoxia inducible VEGF plasmid for ischemic disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hypoxia inducible VEGF plasmid for ischemic disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2640495